However, the ACSL4 inhibitor rosiglitazone could inhibit the production of proinflammatory cytokines and the development of DN by reducing the levels of lipid peroxidation products, MDA and iron, leading to the blockade of ferroptosis in renal tubular cells (Ferrè et al., 2016; Kim et al., 2021; Huang et al., 2022; Wu et al., 2022). The gene discussed is ACSL4; the disease is liver dysplastic nodule.